# US 2010/0137226 A1 · Fatigue-reducing agent

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0137226 A1
- Document ID: US20100137226A1
- Status: Published application
- Kind: A1
- Application number: 12/303,613
- Filed: 2007-06-07
- Published: 2010-06-03
- Earliest claimed: 2006-06-07
- Assignees: Kyowa Hakko Bio Co., Ltd.
- Inventors: Miho Komatsu; Koji Morishita; Takeshi Shibasaki; Itaru Toda
- Web page: https://patentgrep.com/patent/US20100137226A1

## CPC

- A23L 33/175: Amino acids
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 38/063: {Glutathione}
- A61P 3/02: Nutrients, e.g. vitamins, minerals
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

A pharmaceutical product, a functional food or the like has been demanded which can reduce the fatigue in a tired person and enables the tired person to lead a fulfilled life. Disclosed is a fatigue-reducing agent. The fatigue-reducing agent comprises ornithine or a salt thereof and glutathione or a salt thereof as active ingredients.

## Claims

### Claim 1

A fatigue-reducing agent comprising, as active ingredients, ornithine or a salt thereof and glutathione or a salt thereof.

### Claim 2

A method for reducing fatigue, which comprises administering to a subject in need thereof effective amounts of ornithine or a salt thereof and glutathione or a salt thereof.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The fatigue-reducing agent according to claim 1, wherein the ornithine or a salt thereof is L-ornithine or a salt thereof.

### Claim 5 (depends on 1)

The fatigue-reducing agent according to claim 1, wherein the salt of ornithine is selected from the group consisting of hydrochloride, citrate, malate, α-ketoglutarate, and aspartate.

### Claim 6 (depends on 1)

The fatigue-reducing agent according to claim 1, wherein the glutathione or a salt thereof is reduced glutathione or a salt thereof.

### Claim 7 (depends on 1)

The fatigue-reducing agent according to claim 1, wherein the glutathione or a salt thereof is oxidized glutathione or a salt thereof.

### Claim 8 (depends on 6)

The fatigue-reducing agent according to claim 6, wherein the salt of reduced glutathione is selected from the group consisting of hydrochloride, citrate, malate, α-ketoglutarate, and aspartate.

### Claim 9 (depends on 7)

The fatigue-reducing agent according to claim 7, wherein the salt of oxidized glutathione is selected from the group consisting of hydrochloride, citrate, malate, α-ketoglutarate, and aspartate.

### Claim 10 (depends on 1)

The fatigue-reducing agent according to claim 1, wherein the composition ratio of the ornithine or a salt thereof to the glutathione or a salt thereof is 1:100 to 100:1 by weight.

### Claim 11 (depends on 1)

The fatigue-reducing agent according to claim 1, wherein the composition ratio of the ornithine or a salt thereof to the glutathione or a salt thereof is 1:50 to 50:1 by weight.

### Claim 12 (depends on 1)

The fatigue-reducing agent according to claim 1, wherein the composition ratio of the ornithine or a salt thereof to the glutathione or a salt thereof is 10:1 to 1:10 by weight.

### Claim 13 (depends on 1)

The fatigue-reducing agent according to claim 1, wherein the ornithine or a salt thereof and the glutathione or a salt thereof are contained in an amount of 0.5 to 70% by weight.

### Claim 14 (depends on 1)

The fatigue-reducing agent according to claim 1, wherein the ornithine or a salt thereof and the glutathione or a salt thereof are contained in an amount of 1 to 50% by weight.

### Claim 15 (depends on 2)

The method for reducing fatigue according to claim 2, wherein the administration is oral.

### Claim 16 (depends on 2)

The method for reducing fatigue according to claim 2, wherein the administration is non-oral, and the ornithine or a salt thereof and the glutathione or a salt thereof are contained in a sterilized aqueous preparation that is isotonic to the subject's blood.

### Claim 17 (depends on 2)

The method for reducing fatigue according to claim 2, wherein the subject is a human adult and the administration is at a daily dose of 50 mg to 30 g per adult in terms of the ornithine or a salt thereof and the glutathione or a salt thereof.

### Claim 18 (depends on 2)

The method for reducing fatigue according to claim 2, wherein the subject is a human adult and the administration is at a daily dose of 100 mg to 10 g per adult in terms of the ornithine or a salt thereof and the glutathione or a salt thereof.

### Claim 19 (depends on 2)

The method for reducing fatigue according to claim 2, wherein the subject is a human adult and the administration is at a daily dose of 200 mg to 3 g per adult in terms of the ornithine or a salt thereof and the glutathione or a salt thereof.
